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squares (OLS) regression and Tobit regression, with utility score as independent
variable, and ordered logistic regression for each item of EQ-5D. Model perfor-
mance was assessed by comparing predicted and observed mean EQ-5D scores in
the validation set, the unadjusted R-squared and the root mean squared error
(RMSE). RESULTS: The OLS regression had the best predictive performance with
R-squared equal to 0.60 and RMSE equal to 0.25. The linear regression model accu-
rately estimated the mean EQ-5D score in the validation set (predicted score 0.32
versus observed score 0.30). RMSE values of 0.26 and 0.31 were obtained with Tobit
model and ordered logistic model. Items with the greatest contribution to variance
in the OLS model were ‘difficulty of tie the laces of my shoes’ (p0.0018), ‘difficulty
to drink without spilling’ (p0.0156) and ‘difficulty to make precise movements’
(p0.0165). CONCLUSIONS: EQ-5D utility scores can be reasonably predicted from
the H-QoL-I, although item wordings are not directly related. The model based on
OLS regression provides the best fitting. Motor functions items contributed the
model to utility predictions.
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OBJECTIVES: In patients with RMS, assess the impact of relapse(s) leading to hos-
pitalization on Health-Related Quality of Life (HR-QoL), fatigue and Health Care
resource utilisation. METHODS: TEMSO (N1088) was designed to assess efficacy
and safety of teriflunomide, a novel oral disease modifier, in RMS patients. Patients
with no relapse, patients with relapse(s) not leading to hospitalisation and patients
with at least one relapse leading to hospitalisation were analysed. The following
patient reported outcomes (PROs) were assessed; utility (EQ5D), PCS and MCS
(Physical and Mental Health Component Summaries) scores of the SF-36, fatigue
(FIS-total score). Also, Emergency Medical Facility Visits (EMFV; a visit to a medical
facility/hospital for emergency care not resulting in an admission) was tracked.
Changes from Baseline for PROs and annual EMFV rate were analysed for a two-
year period. RESULTS: Change from baseline (CfB) in utility in patients with no
relapse was 0.034, CfB in utility in patients with relapse(s) not leading to hospi-
talisation was -0.019(*p10.01) and CfB in utility in patients with relapse(s) leading
to hospitalisation was -0.057(p10.001; p2:ns). Similar results were seen for PCS of
1.0, -1.0 (p10.01) and -3.1(p10.001; p20.05) respectively and for MCS were
respectively 1.8, -1.0(p10.01) and -2.7 (p10.001; p2:ns). This same trend was
observed with FIS total score, (CfB was respectively: -3.0, 1.4 (p1:ns) and 10.3
(p10.001; p20.01). The mean annual EMFV rate in patients with no relapse was
0.5 and in patients with relapse not leading to hospitalisation was 0.4 (p1:ns). This
rate was increased to 1.2 (p10.05; p20.001) in patients with relapse leading to
hospitalisation. CONCLUSIONS: In TEMSO, patients with relapse leading to hospi-
talisation comparatively have worsening in HR-QoL (EQ-5D, SF-36), fatigue and
have a higher number of EMFV. *p1: versus patients with no relapse, p2: versus
patients with relapse not leading to hospitalisation.
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OBJECTIVES: The original SAT is a five-item questionnaire developed to assess
treatment benefits associated with application of QUTENZA™, a novel high-dose
capsaicin patch, in clinical trials among patients with neuropathic pain . The ob-
jective of this study was to evaluate the item performance and psychometric prop-
erties of the SAT. METHODS: The SAT, Numerical Pain Rating Scale (NPRS), SF-36,
Brief Pain Inventory and Patient Global Impression of Change (PGCI) scores were
measured in two 12 week Phase3 clinical trials. Descriptive statistics, exploratory
and confirmatory factor analysis (EFA and CFE) were conducted to assess the item
performance and to explore the underlying constructs. Reliability and validity were
also examined. RESULTS: Pooled data from 698 patients (21-91 years) completing
SAT after 12 weeks of treatment were analyzed. From descriptive statistics, EFA
and CFA results, a one-factor model combining 4 of the 5 items emerged as the
optimal solution with 66% explained variance. The internal consistency reliability
was high (Cronbach’s alpha  0.87). Construct validity was demonstrated by mod-
erate to high correlations with change in the NPRS (-0.55 pain now and -0.64 aver-
age pain), BPI (-0.59 worst pain, -0.35 activity limitation), SF 36v2 pain subscale
(0.43) and PGIC (0.85). SAT scores strongly discriminated patient change groups
using the PGIC; mean SAT scores were 1.7 in patients who were very much im-
proved versus -1.0 in patients who were much worse/very much worse.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
the four-item version of SAT are valid and reliable for patients self assessment of
treatment with QUTENZA™ among patients with neuropathic pain. The item per-
formance suggests that the questionnaire could be further improved with addi-
tional patient input to clarify some of the questions as well as revising the response
options and recall period to better reflect treatment benefits during the course of a
trial.
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OBJECTIVES: The original 40-question Fabry-specific Paediatric Health and Pain
Questionnaire (FPHPQ) was developed to understand and assess the symptoms in
Fabry Disease (FD) patients as no validated instrument existed. The objective of
this study was to evaluate the psychometric properties of the FPHPQ. METHODS:
FPHPQ data were collected from the FOS, a registry sponsored by Shire HGT for
patients with FD who were treatment naive or receiving enzyme replacement ther-
apy with agalsidase alfa. Descriptive statistics and exploratory factor analysis were
conducted to assess the item performance and to explore the underlying con-
structs. Reliability, validity, and responsiveness were also examined. RESULTS:
Eighty-seven children (aged 4-18 years) from 8 different countries completed the
questionnaire. From descriptive statistics and EFA, 23 items in three subscales
emerged: Pain associated with heat or exertion; pain associated with cold; abdom-
inal pain and fatigue. Internal consistency reliability for all three subscales was
good (Cronbach alpha  0.84) and high for all age groups (4-7, 8-12, 13-18 years).
Test-retest reliability was high for all three subscales (intraclass correlation coef-
ficient  0.74). Construct validity was demonstrated by moderate correlation with
the Brief Pain Inventory (BPI), KINDL, and EQ-5D. Known group validity showed that
all subscales were able to discriminate between mild and moderate FD severity as
classified by the FOS MSSI (Mainz Severity Score Index). The FPHPQ heat and exer-
tion subscale was responsive to change in symptoms between responders and
non-responders as defined by change in EQ-5D index scores between Visits 1 and 2.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
FPHPQ are valid and reliable for assessing patient-reported symptoms of FD. The
questionnaire could be a useful tool for clinicians to understand the progression of
disease and monitor treatment effects. FPHPQ will be further validated and refined
as the FOS database is continuously adding more patients.
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OBJECTIVES: PatientsLikeMe is an online health-data sharing community and re-
search platform for patients with chronic and life-changing health conditions. In
developing the PatientsLikeMe online platform for patients with Multiple Sclerosis
(MS), we required a patient-reported, multi-dimensional assessment of functional
status that was easy to complete. Existing measures of functional status were
inadequate; clinician-reported, focused on walking, and burdensome to complete.
To develop a longitudinal record accessible to patients using the site, we developed
the Multiple Sclerosis Rating Scale (MSRS). METHODS: We adapted a clinician-
rated measure, the Guy’s Neurological Disability Scale, to a self-report scale and
deployed it to an online community. As part of our validation process, we reviewed
online forum discussions between patients, conducted in-person patient cognitive
debriefing, and made minor improvements to form a revised scale (MSRS-R). The
MSRS-R was deployed as a cross-sectional survey to 4382 patients with relapsing-
remitting MS (RRMS) on the PatientsLikeMe platform. The survey included the
MSRS-R as well as a range of comparator MS measures: PRIMUS, MSIS-29, PDDS,
NARCOMS Performance Scales, and MSWS-12. RESULTS: In total, 816 RRMS pa-
tients responded. The MSRS-R exhibited high internal consistency (Cronbach’s
alpha 0.86) and 1-week retest reliability (r 0.91). The MSRS-R walking item was
highly correlated with alternative walking measures (PDDS, r 0.84; MSWS-12, r
0.83; NARCOMS mobility question, r 0.86). The MSRS-R correlated well with com-
parison instruments, and reliably differentiated between participants by PDDS dis-
ease stage, relapse severity, and time since diagnosis. Retrospective scoring of
most recent relapse suggested a 3-point increase in MSRS-R might usefully identify
relapses. CONCLUSIONS: The MSRS-R is a concise, multi-faceted measure of MS-
related functional disability. It may be useful for describing the impact of MS and
can support further inquiry into the factors that relate to variation in outcomes
among MS patients.
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OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is a first self-
reported specific Health-Related Quality of Life (HR-QoL) instrument developed to
assess the QoL of patients suffering from Huntington’s disease. It was originally
developed and validated in French and in Italian. The instrument is being validated
in 11 languages. This study aims to validate the German, Polish and US versions of
H-QoL-I cross-culturally. METHODS: The original questionnaire was based on 11
items and 3 dimensions. The instrument was translated forwards and backwards
by native speakers. It was then reviewed and adjusted by local clinicians and tested
for face validity. A survey was conducted with 134 US, 60 Polish and 41 German
patients. Face validity was tested through item completion and overall under-
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standing. Internal validity was tested, assessing internal consistency, correlation
matrix using item/dimension correlation, factorial structure and differential item
functioning. External validation was performed versus motor symptoms, behav-
ioral symptoms, and the well-established QoL scale EuroQoL 5D. RESULTS: The
preliminary analysis supported the validity of the H-QoL-I. Face validity appeared
satisfactory (Missing data 7%); as for the original instrument, a ceiling effect was
observed for patients with severe HD. The H-QoL-I showed an acceptable reliability
(Cronbach’s alpha 0.85 for each dimension). The factor analysis explained 77% of
the total variance and split the items in 3 factors in the same way as the original
version. There was no differential item functioning neither between countries nor
gender. The Pearson’s correlation between the clinical motor score and the motor
functioning dimension was 0.89, between EQ-5D score and H-QoL-I total score, 0.71
and between the clinical depression/anxiety score and the psychological dimen-
sion of H-QoL-I, 0.63. CONCLUSIONS: Test–retest and sensitivity to change remain
to be performed, but current data support the validity of the H-QoL-I.
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OBJECTIVES: The H-CSRI is the first clinimetric patient assessed scale for patients
with Huntington’s disease (HD). It was originally developed and validated for
France and Italy. Such an instrument offers the advantage of allowing a remote
follow-up and getting information on the development of motor, functional and
behavioral disorders of HD patients perceived by the patient himself. The objective
of this study is to adapt and cross-culturally validate the H-CSRI for Germany,
Poland and USA. METHODS: The original questionnaire included three subscales
assessing the motor (13 Likert-type items in 4 dimensions), functional (7 Yes/No
questions) and behavioural ability (13 Likert-type items in 4 dimensions). The in-
strument was translated forwards and backwards by native speakers. It was then
reviewed and adjusted by local clinicians and tested for face validity. A total of 134
US, 60 Polish and 41 German HD patients filled in the H-CSRI questionnaire. Clas-
sical test theory and item response theory were used to assess its clinimetric prop-
erties.Cross-cultural validation was assessed by diferential item functioning
analysis. RESULTS: Among 235 patients, item response rates ranged from 86% to
93%. Face validity appeared satisfactory; as for the original instrument, there was a
floor effect on items related to psychotic disorder in the behavioral dimension. The
H-CSRI showed an acceptable reliability (Cronbach’s alphas 0.80). Factor analyses
demonstrated a satisfactory construct validity for the motor dimensions with 76%
of explained variance and for the behavioural dimensions with 74% of the ex-
plained variance. The differential item functioning analyses showed no item bias
between the three countries and between genders. CONCLUSIONS: These data
support the cross-cultural validity of the H-CSRI to assess the health status for
patients with Huntington’s disease and integrate the patient perspective for Ger-
many, Poland and US.
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OBJECTIVES: Ichthyoses form a group of ailments for which the main part of treat-
ment aims to reduce hyperkeratosis and to control sensory, articular and psycho-
logical complications. In infants, dermatologists do not restrict their treatment to
the cutaneous involvement, but endeavour to prevent the consequences of these
severe and obvious afflictions for the future of these patients. To explore the hand-
icap, in the largest sense, generated by ichthyosis using a questionnaire to express
the burden of the illness on the daily life of patients and their family, in order to
anticipate and treat it more effectively. METHODS: The questionnaire was devel-
oped following a strict methodological process involving a multidisciplinary team
incorporating various players (doctors, nurses, social workers) who are involved in
the treatment of patients and caring for their families in order to guarantee its
credibility and reliability. A review of the literature and discussions with the chil-
dren and their families were conducted in order to identify the concepts related to
the pathology. RESULTS: Exploratory assessments showed that the concept of
burden could be structured around five components: feeling of pain, daily life,
family and personal relationships, work and psychological impact. Ninety-six pre-
liminary items were identified at the end of the first discussion. A first analysis
managed to reduce these items to 40 whilst conserving the 5 components but
making it easier to use the analysis. The creation of a child module aimed at
children who are able to provide answers independently proved necessary.
CONCLUSIONS: Chronic pathologies such as ichthyosis, which remains a rare and
incapacitating illness, are difficult to assess by clinical or quality of life aspects alone as
their impact can be multidimensional. Family Burden Ichthyosis takes them all into
consideration in order to explain every angle of the handicap generated.
PND49
INITIAL PSYCHOMETRIC PROPERTIES OF THE EURODOLMED QUESTIONNAIRE:
A NEW INSTRUMENT TO MEASURE NEUROPATHIC PAIN IN PATIENTS WITH
SPINAL CORD INJURY (SCI) BASED ON PAIN INTENSITY, PAIN INTERFERENCE
AND PAIN DESCRIPTORS
Taylor JS1, Ruiz MA2, Soler MD3, Bouhassira D4, Poole H5, Jauregui ML6, Eurodolmed SG7,
Finnerup NB8
1Hospital Nacional de Parapléjicos SESCAM, TOLEDO, Spain, 2Universidad Autonoma de Madrid,
Madrid, Spain, 3Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain,
4Hôpital Ambroise Paré, Boulogne-Billancourt, France, 5Walton Centre, Liverpool, Liverpool, UK,
6Hospital Cruces, Barakaldo, Bizkaia, Spain, 7Hospital Nacional de Parapléjicos, Toledo, Toledo,
Spain, 8Aarhus University Hospital, Århus C, Århus, Denmark
OBJECTIVES: To develop a new instrument measuring neuropathic pain at and
below the level of spinal cord injury (SCI) based on pain intensity, pain interference
and pain descriptors. METHODS: An expert panel composed of pain specialists,
physiologists, rehabilitation doctors, neurologists, psychologists and methodolo-
gists was created to generate the items and to supervise the questionnaire con-
struction, following Classic Test Theory assumptions. A total of 12 Likert items, 2
multichoice items, 7 dichotomous indicators and 23 pain descriptors were pro-
posed. They were measured for at and below level pain in patients with traumatic
SCI between the C3 and T10 level. A subgroup of items was assessed for constant
pain, paroxysmal pain, and evoked pain. Item analysis, structural validity (explor-
atory factor analysis) and reliability (Cronbach’s alpha) were assessed. Correlation
with DN4, NPSI, BPI and MHI5 was studied for convergent validity. Cluster analysis
and multidimensional correspondence analysis were also used to study pain de-
scriptor behavior. RESULTS: A total of 153 patients recruited at 4 specialized hos-
pitals in Spain and Denmark. Women were 26%, and mean age 43 years (SD12.4).
Thirty five percent experienced below SCI level pain, 26% at level, and 39% both.
Factor analysis below SCI suggested that pain intensity and QoL interference were
related to constant non-evoked pain, while paroxysmal pain was related to night
disturbance and temperature-evoked pain. Scale reliability was 0.76 below and 0.80
at SCI level. Exploratory correlations with other standard diagnostic tools were
moderate. Descriptor clustering disclosed 5 main groups of pain types covering
most of the items used frequently in other instruments (DN4 or NPSI). Pain at and
below level differed in specific aspects. CONCLUSIONS: Initial psychometric prop-
erties of the EuroDolMed are good and support the use of this new instrument to
explore neuropathic pain in patients with SCI, although an effort should be made to
shorten it without losing precision.
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OBJECTIVES: To assess public preferences for the predictive genetic test for Alz-
heimer’s disease in the United States. METHODS: A rating conjoint analysis was
conducted using an anonymous online survey distributed by Qualtrics® to a gen-
eral population panel in April 2011 in the United States. The study design included
three attributes: Accuracy, Treatment Availability, and Anonymity. A total of 12
scenarios were used to elicit people’s preference by adopting an 11-point scale. The
respondents also stated their highest willingness-to-pay (WTP) for each scenario
by answering the open-ended questions. RESULTS: A total of 295 responses were
collected over four days. The results showed the most important attribute for the
aggregate model was Accuracy, contributing 64.73% to the preference rating. Treat-
ment Availability and Anonymity contributed 20.72% and 14.59% to the preference
rating, respectively. The most preferred scenario was the test with a 100% chance
of being correct, a cure for AD is available and the test result is anonymous. The
median WTP for the highest-rating scenario (Accuracy 100%, a cure is available,
test result is anonymous) was $100 (mean WTP was $276). The median WTP for the
lowest-rating scenario (Accuracy 40%, no cure but drugs for symptom relief, not
anonymous) was zero (mean WTP was $36). Four groups were identified using
cluster analysis revealing different patterns of importance among the three
attributes. CONCLUSIONS: The results of this study highlight the attributes con-
sumer find important when making the decision to obtain an AD genetic test.
These results should be of interests to policy makers, genetic test developers and
health care providers.
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OBJECTIVES: Previous research suggests that the Short Form 36 (SF-36) may cap-
ture some of the broad effects of MS that are not reflected in the Kurtzke Expanded
Disability Status Scale (EDSS) and may be appropriate when evaluating overall
health-related quality of life (HRQL). The purpose of this study was to explore the
relationship between an EDSS-correlated self-reported disability measure, the Pa-
tient Determined Disease Steps (PDDS), and SF-36 health domain scores.
METHODS: A convenience sample of US-residing participants with MS were re-
cruited through web-based patient advocacy organizations. Participants re-
sponded to questions pertaining to demographics, disease history, productivity,
urinary symptoms, and HRQL. Disability status was measured using the PDDS, an
8-point ordinal scale ranging from “Normal” to “Bedridden,” and general HRQL was
measured using the SF-36 version 2, a 36-item questionnaire comprised of 8 health
domain subscales and 2 summary scores normalized for direct comparison to the
US general population. Spearman rank correlation coefficients were calculated to
assess the relationship between SF-36 health domain scores and PDDS scores.
RESULTS: Among the sample of 1052 participants who completed the survey, 19%
were men and the mean age was 48 years. All 8 SF-36 subscales were significantly
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